Search results for "Drug Implants"

showing 10 items of 19 documents

Clinical Decision-Making when Treating Diabetic Macular Edema Patients with Dexamethasone Intravitreal Implants.

2017

Diabetes mellitus (DM) is a metabolic disease frequently associated with comorbidities that include diabetic macular edema (DME). The current medical approach to treating DME involves intravitreal injections with either anti-vascular endothelial growth factors or steroids. However, the burden associated with intravitreal injections and DM-derived complications is high, underlining the need to find optimal treatment regimens. In this article we describe the considerations we apply when treating DME patients with dexamethasone intravitreal implants (Ozurdex®), particularly those that influence the clinical decision-making process during the follow-up period. These considerations are based bot…

0301 basic medicinemedicine.medical_specialtyVisual acuitygenetic structuresClinical Decision-MakingVisual AcuityDexamethasoneMacular Edema03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusDexamethasone Intravitreal ImplantMedicineHumansMacular edemaGlucocorticoidsDexamethasoneDrug ImplantsDiabetic Retinopathybusiness.industryGeneral MedicineDiabetic retinopathymedicine.diseaseeye diseasesSensory SystemsPathophysiologyOphthalmology030104 developmental biologyIntravitreal Injections030221 ophthalmology & optometrymedicine.symptombusinessTomography Optical Coherencemedicine.drugMedical literatureOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
researchProduct

Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results

2021

Purpose: To report visual and anatomical outcomes of chronic/refractory diabetic macular edema (DME) treated with intravitreal fluocinolone acetonide implant. Setting: Retrospective, one arm, multicentric study. Method: Between 2013 and 2018, 27 consecutive eyes of 25 patients with chronic/refractory DME were treated with a fluocinolone acetonide intravitreal implant. Best registered visual acuity (BRVA), central retinal thickness (CRT), and Goldmann tonometry intraocular pressure (IOP) were assessed at 12 and 24 months. The need for IOP lowering treatment as well as top-up therapy during the follow-up were also assessed. Results: The duration of DME prior to treatment in our study was 54 ±…

0301 basic medicinemedicine.medical_specialtygenetic structuresDiabetic macular edemaMacular EdemaRetina03 medical and health sciences0302 clinical medicineRefractoryFluocinolone acetonideOphthalmologyDiabetes MellitusHumansMedicineGlucocorticoidsRetrospective StudiesDrug ImplantsDiabetic Retinopathybusiness.industryGeneral Medicineeye diseasesOphthalmology030104 developmental biologyFluocinolone AcetonideIntravitreal Injections030221 ophthalmology & optometryImplantbusinessmedicine.drugEuropean Journal of Ophthalmology
researchProduct

Widening use of dexamethasone implant for the treatment of macular edema

2017

Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo Department of Ophthalmology, University of Catania, Catania, Italy Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of effica…

3003intravitrealgenetic structuresimplantmedicine.medical_treatmentPharmaceutical ScienceVitrectomyReviewDrug Implantcorticosteroids0302 clinical medicineGlucocorticoidCentral retinal vein occlusionDrug DiscoveryDelayed-Action PreparationCorticosteroidRandomized Controlled Trials as TopicDrug ImplantsCorticosteroids; Dexamethasone; Implant; Intravitreal; Macular edema; Pharmacology; 3003; Drug Discovery3003 Pharmaceutical ScienceDiabetic retinopathyIntravitreal InjectionsUveitismedicine.drugHumanmedicine.medical_specialtydexamethasone03 medical and health sciencesOphthalmologymedicineHumansMacular edemaGlucocorticoidsDexamethasonePharmacologyMacular edemaDiabetic Retinopathybusiness.industryIntravitreal InjectionDrug Discovery3003 Pharmaceutical Sciencelcsh:RM1-950Macular degenerationmedicine.diseaseeye diseasesSurgerylcsh:Therapeutics. PharmacologyDelayed-Action Preparations030221 ophthalmology & optometryBranch retinal vein occlusionsense organsbusiness030217 neurology & neurosurgeryDrug Design, Development and Therapy
researchProduct

Differential expression of the corticosteroid receptors GR1, GR2 and MR in rainbow trout organs with slow release cortisol implants

2012

The present study describes the transcriptional levels of the corticosteroid receptors (CRs) GR1, GR2 and MR in the different organs of the rainbow trout (Oncorhynchus mykiss) in response to a slow release of cortisol, throughout a 10-day period. We show that after short term (1 day after cortisol implantation), when the plasma levels of cortisol emulate an acute stress, the GR2 and MR expression levels were upregulated in the brain and head kidney tissues. This result reflects the role of these organs as regulators of the stress response. In general, the rest of the organs, especially gills, intestine, liver, muscle and spleen, showed decreased transcriptional levels of GR1, GR2 and MR, al…

Blood GlucoseFish Proteinsendocrine systemmedicine.medical_specialtyHydrocortisoneTranscription GeneticPhysiologymedicine.drug_classSpleenBiologyHematocritCarbohydrate metabolismBiochemistryReceptors GlucocorticoidDownregulation and upregulationStress PhysiologicalInternal medicinemedicineAnimalsChronic stressLactic AcidReceptorMolecular BiologyDrug Implantsmedicine.diagnostic_testOxygen transportBrainHead KidneyUp-RegulationReceptors Mineralocorticoidmedicine.anatomical_structureEndocrinologyOrgan SpecificityOncorhynchus mykissCorticosteroidhormones hormone substitutes and hormone antagonistsComparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology
researchProduct

The occurrence of serological H-Y antigen (Sxs antigen) in the diandric protogynous wrasse, Coris julis (L.) (Labridae, Teleostei)

1987

Abstract The serological sex-specific (Sxs) antigen (previously called ‘H-Y antigen’) has been shown, in various vertebrate species ranging from fish to mammals, to be characteristic of the heterogametic sex. We studied a protogynous hermaphrodite, Coris julis , in order to examine whether the change of a female to a secondary male also involves a change in the Sxs-antigen phenotype. The (homogametic) females of this species were found to be Sxs negative, while both primary and secondary males were Sxs positive. This was true not only for gonads but also for nongo-nadal tissues. The administration of androgen to females is known to cause sex inversion in this species; we were able to demons…

Cytotoxicity ImmunologicMaleCancer Researchmedicine.drug_classH-Y AntigenCorisZoologyEnzyme-Linked Immunosorbent AssayBiologyAntigenHermaphroditeTestismedicineAnimalsTestosteroneMolecular BiologyDrug ImplantsH-Y antigenOvaryFishesCell BiologyAnatomySex reversalAndrogenbiology.organism_classificationSpermatogoniaWrasseOocytesFemaleHeterogametic sexDevelopmental BiologyDifferentiation
researchProduct

Intraoperative dexamethasone intravitreal implant in diabetic macular edema patients undergoing phacoemulsification: The CataDex study

2021

Purpose To assess the impact of preoperative intravitreal dexamethasone implant (DexI) on functional and anatomic outcomes in patients with diabetic macular edema (DME) who underwent phacoemulsification cataract surgery. Methods Prospective and non-comparative study conducted on consecutive DME patients undergoing cataract surgery. DexI was administered 15 days before surgery and in a pro re nata regime after surgery. Main outcome measures were mean change in central retinal thickness (CRT), central subfield thickness (CST), total macular volume (TMV), and central subfield volume (CSV) from baseline to month-12. Secondary outcome was mean change in best corrected visual acuity (BCVA). Resul…

Drug ImplantsDiabetic Retinopathygenetic structuresSettore MED/30 - Malattie Apparato Visivoreal worldGeneral Medicineeye diseasesDexamethasoneMacular EdemaOphthalmologycataractIntravitreal InjectionsphacoemulsificationDiabetes MellitusHumansProspective StudiesDexamethasone implantdiabetic macular edemaGlucocorticoidsTomography Optical Coherence
researchProduct

Microfibrillar polymeric ocular inserts for triamcinolone acetonide delivery.

2019

Abstract Despite eye drops generally represent the most convenient, simple and patient-friendly formulations to treat ocular diseases, they suffer from poor retention on the ocular surface and low drug bioavailability leading to the necessity of prolonged and continuous treatment over time. Therefore, ocular insert could represent an innovative way to benefit from ocular topical administration while minimizing all the relevant limitation related to this route of administration. Polymeric non-erodible mucoadhesive ocular inserts should be comfortable and should rapidly adhere on the ocular surface, remain in situ for prolonged period, assure a reproducible and controlled drug release as well…

DrugTriamcinolone acetonidegenetic structuresPolymersmedia_common.quotation_subjectPoly(butylene succinate) (PBS)Pharmaceutical ScienceAdministration Ophthalmic02 engineering and technologyAbsorption (skin)Eye030226 pharmacology & pharmacyTriamcinolone Acetonide03 medical and health sciencesRoute of administration0302 clinical medicinemedicineMucoadhesionAnimalsHumansSettore BIO/15 - Biologia FarmaceuticaButylene GlycolsGlucocorticoidsmedia_commonDrug ImplantsElectrospinningPlasma-assisted surface functionalizationChemistry021001 nanoscience & nanotechnologyeye diseasesBioavailabilityPolyesterDrug LiberationSurface modificationCattleOcular insert0210 nano-technologymedicine.drugBiomedical engineeringInternational journal of pharmaceutics
researchProduct

Drug delivery from the oral cavity: focus on a novel mechatronic delivery device

2007

Dental drug delivery systems have been used for a long time, in particular for the local therapy of diseases affecting the oral cavity. Research today concentrates on the design of formulations to increase their retention time. Even today, however, prosthetic devices incorporating drug delivery are rarely used. Mainly, they are focused on prophylaxis and the release of antibacterial agents. However, as buccal delivery, because of its undeniable advantages, has become popular for systemic drug delivery, and prolonged well-controlled release has been identified as beneficial, especially for chronic diseases, a new class of delivery systems is evolving: highly miniaturized computerized deliver…

Drugmedicine.medical_specialtymedia_common.quotation_subjectDentistryAdministration OralOral cavityDrug Delivery SystemsPharmaceutical technologyDrug DiscoverymedicineHumansIntensive care medicinemedia_commonPharmacologyDrug Implantsbusiness.industryMouth MucosaAdministration BuccalBuccal administrationEquipment DesignDental drug delivery Intra-oral drug delivery Dental prosthetic drug delivery Buccal delivery Controlled drug delivery MEMSDrug Therapy Computer-Assistedstomatognathic diseasesDrug deliveryDelivery systembusinessRetention time
researchProduct

Development of a long-lasting ventricular catheter impregnated with a combination of antibiotics.

2003

A ventricular silicone catheter impregnated with a combination of rifampin and a quinolone was developed in order to prevent ventricular shunt related infections. As model substance for the quinolones we used sparfloxacin, because of its specific physicochemical properties resulting in a quantitative detection also in the presence of a second antibiotic. In our study we focused especially on an optimization of the antibiotic release out of the impregnated catheters in order to develop long lasting devices with a broad antimicrobial spectrum. A release-optimized catheter was tested with an in vitro colonization test and additionally with a method developed to examine the spread of bacteria o…

Long lastingmedicine.medical_specialtyProsthesis-Related Infectionsmedicine.drug_classAntibioticsBiophysicsBioengineeringQuinolonesCerebral VentriclesBiomaterialschemistry.chemical_compoundSiliconeCatheters IndwellingDrug Delivery SystemsCoated Materials BiocompatibleStaphylococcus epidermidismedicineStaphylococcus epidermidisDrug Implantsbiologybusiness.industrySterilizationbiology.organism_classificationAntimicrobialQuinoloneSurgeryAnti-Bacterial AgentsEquipment Failure AnalysisCatheterSparfloxacinchemistryMechanics of MaterialsCeramics and CompositesEquipment ContaminationDrug Therapy CombinationRifampinbusinessmedicine.drugBiomaterials
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct